hCG Monotherapy Dosage and Schedule in Hypogonadotropic Hypogonadism
For men with hypogonadotropic hypogonadism seeking fertility or virilization, initiate hCG at 1,500-2,000 IU intramuscularly or subcutaneously 2-3 times per week, with dose titration based on testosterone response and clinical outcomes. 1
Standard Dosing Protocols
The most commonly recommended regimens based on guideline evidence are:
Initial Treatment Phase
- 1,500-2,000 IU intramuscularly 2-3 times weekly for the first 3-6 months 1
- Alternative FDA-approved regimen: 500-1,000 IU three times weekly for 3 weeks, followed by the same dose twice weekly for 3 weeks 2
- Higher intensity option: 4,000 IU three times weekly for 6-9 months, then reduced to 2,000 IU three times weekly for an additional 3 months 2
Route of Administration
Both intramuscular and subcutaneous routes are effective. Subcutaneous self-administration is preferred as it produces comparable testosterone levels to intramuscular injection, is well-tolerated, and allows patient autonomy 3. Research demonstrates that subcutaneous hCG (5,000 IU twice weekly) produces equivalent cumulative serum and salivary testosterone levels compared to intramuscular administration 3.
Treatment Objectives and Monitoring
Expected Outcomes
- Testicular growth typically occurs within 2-3 months of initiating therapy 4, 5
- Progressive virilization develops with continued treatment 1
- Spermatogenesis may require 6-12 months or longer 6, 7
Clinical Response Indicators
Monitor the following parameters:
- Testicular volume (should increase from baseline)
- Serum testosterone levels (target normal adult range)
- Development of secondary sexual characteristics
- Symptom improvement (physical strength, libido)
Research shows that in 64 men with central hypogonadism treated with hCG 1,500 IU twice weekly, testicular volume increased significantly from 3.08 ± 2.44 ml to 8.92 ± 5.37 ml (P < 0.001), with 81.2% showing effective response 6.
Important Clinical Considerations
When to Add FSH
Recent evidence suggests initiating FSH alone for 2-4 months before starting hCG may improve subsequent fertility outcomes with shorter treatment duration required to obtain spermatozoa 1. However, when hCG monotherapy is chosen, FSH should be added if:
- Inadequate testicular growth after 6 months
- Insufficient testosterone response
- Failure to achieve spermatogenesis after 12 months of hCG alone
Dose Titration Strategy
A novel approach involves titrating hCG dose to reduce anti-Müllerian hormone (AMH) by 50% rather than simply normalizing plasma testosterone 7. This strategy achieved spermatogenesis in 76.7% of patients with a median time of 12 months, using lower hCG doses (500 IU three times weekly) combined with FSH and testosterone supplementation 7.
Predictors of Response
Baseline factors associated with better outcomes include:
- Larger baseline testicular volume
- Higher serum inhibin B levels
- Detectable AMH levels
- Absence of severe testicular pathology
Common Pitfalls to Avoid
- Starting with insufficient doses: Low doses (under 1,500 IU) are often ineffective 8
- Premature discontinuation: Allow at least 6-12 months before judging treatment failure
- Inadequate monitoring: Check testosterone levels and testicular volume every 3 months
- Missing the window for FSH addition: If no testicular growth by 6 months, add FSH rather than continuing hCG monotherapy indefinitely
Safety Profile
hCG monotherapy is generally well-tolerated. The primary adverse effects are:
- Injection site reactions
- Gynecomastia (uncommon with appropriate dosing)
- Rarely, excessive testosterone production requiring dose reduction
Contraindications include active male breast cancer and situations where fertility preservation is not desired (in which case direct testosterone replacement is more appropriate) 9.
Maintenance Considerations
Once virilization is achieved and if fertility is no longer a goal, transition to lifelong testosterone replacement therapy (intramuscular testosterone enanthate 250 mg every 15-28 days, undecanoate every 10-14 weeks, or transdermal gel) unless contraindications exist 1.